

Literaturverzeichnis

- Abraham I, Chin KV, Gottesman MM, Mayo JK, Sampson KE: Transfection of a mutant regulatory subunit gene of cAMP-dependent protein kinase causes increased drug sensitivity and decreased expression of P-glycoprotein. *Exp Cell Res.* 1990, *189 (1)*, S.133-141,
- Agundez JAG, Olivera M, Ladero JM, Rodriguez-Lescure A, Ledesma MC, Diaz-Rubio M, Meyer UA, Benitez J: Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizers. *Pharmacogenetics.* 1996, *6 (6)*, S.501-512,
- Alsenz J, Steffen H, Alex R: Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers. *Pharm Res.* 1998, *15 (3)*, S.423-428,
- Ambudkar SV, Lelong IH, Zhang J, Cardelli CO, Gottesman MM, Pastan I: Partial purification and reconstitution of the human multidrug resistance pump: characterization of the drug-stimulatable ATP hydrolysis. *Proc Natl Acad Sci USA.* 1992, *89 (18)*, S.8472-8476,
- Ameyaw MM, Regateiro F, Li T, Liu X, Tariq M, Mobarek A, Thornton N, Folayan GO, Githang'a J, Indalo A, Ofori-Adjei D, Prince-Evans DA, McLeod HL: MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. *Pharmacogenetics.* 2001, *11 (3)*, S.217-221,
- Azzaria M, Schurr E, Gros P: Discrete mutations induced in the predicted nucleotide-binding sites of the *mdr1* gene abolish its ability to confer multidrug resistance. *Mol Cell Biol.* 1989, *9 (12)*, S.5289-5297,
- Balram C, Sharma A, Sivathasan C, Lee EJ: Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: phenotypic-genotypic correlates. *Br J Clin Pharmacol.* 2003, *56 (1)*, S.78-83,
- Bart J, Groen HJ, Hendrikse NH, van der Graaf WT, de Vaalburg VE: The blood-brain barrier and oncology: new insights into function and modulation. *Cancer Treat Rev.* 2000, *26*, S.449-462,
- Bennett JM, Catovski D, Daniel MT et al.: Proposals for the classification of the acute leukemias. French-American-British (FAB) cooperative group. *Br J Haematol.* 1976, *3*, S.451-458,
- Bernal ML, Sinues B, Fanlo A, Mayayo E: Frequency distribution of C3435T mutation in exon 26 of the MDR1 gene in a Spanish population. *Ther Drug Monitor.* 2003, *25 (1)*, S.107-111,
- Beyermann B, Adams HP, Henze G: Philadelphia chromosome in relapsed childhood acute lymphoblastic leukemia: a matched-pair analysis. The Berlin-Frankfurt-Munster Study Group. *J Clin Oncol.* 1997, *15 (6)*, S.2231-2237,

- Biondi A, Vasecchi MG, Seriu T et al.: Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group. *Leukemia*. 2000, *14*, S.1939-1943,
- Bohnenstengel F, Hofmann U, Eichelbaum M, Kroemer HK: Characterization of the cytochrome P450 involved in the side-chain oxidation of cyclophosphamide in humans. *Eur J Clin Pharmacol*. 1996, *51 (3-4)*, S.297-301,
- Borgmann A, Hartmann R, Schmid H, Klingebiel T, Ebell W, Göbel U, Peters C, Gadner H, Henze G: Isolated extramedullary relapse in children with acute lymphoblastic leukemia: A comparison between treatment results of chemotherapy and bone marrow transplantation. *BFM Relapse Study Group. Bone Marrow Transplant*. 1995, *15*, S.515-521,
- Buchanan GR, Rivera GK, Pollock BH, Boyett JM, Chauvenet AR, Wagner H, Maybee DA, Crist WM, Pinkel D: Alternating drug pairs with or without periodic reinduction in children with acute lymphoblastic leukemia in second bone marrow remission: A Pediatric Oncology Group study. *Cancer*. 2000, *88*, S.1166-1174,
- Bührer C, Hartmann R, Fengler R, Dopfer R, Gadner H, Gerein V, Göbel U, Reiter A, Ritter J, Henze G: Superior prognosis in combined compared to isolated bone marrow relapses in salvage therapy of childhood acute lymphoblastic leukemia. *Med Pediatr Oncol*. 1993, *21*, S.470-476,
- Burian M, Grosch S, Tegeder I, Gesslinger G: Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population. *Br J Clin Pharmacol*. 2002, *54 (5)*, S.518-521,
- Butler MA, Lang NP, Young JF, Caporaso NE, Vineis P, Hayes RB, Teitel CH, Massengill JP, Lawsen MF, Kadlubar FF: Determination of CYP1A1 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. *Pharmacogenetics*. 1992, *2 (3)*, S.116-127,
- Cascorbi I, Gertloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E, Eichelbaum M, Brinkmann U, Roots I: Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. *Clin Pharmacol Ther*. 2001, *69 (3)*, S.169-174,
- Cave H, van der Werff ten Bosch J, Suci S et al.: Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. *European Organization for Research and Treatment of Cancer-Childhood Leukemia Cooperative Group. N Engl J Med*. 1998, *339*, S.591-598,
- Chang TKH, Weber GF, Crespi CL, Waxman DJ: Differential activation of cyclophosphamide and ifosfamide by cytochromes P450 2B and 3A in human liver microsomes. *Cancer Res*. 1993, *53 (23)*, S.5629-5937,

- Chang TKH, Yu L, Goldstein JA, Waxman DJ: Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-K_m catalysts of cyclophosphamide and ifosfamide activation. *Pharmacogenetics*. 1997, 7, S.211-221,
- Chen CJ, Chin JE, Ueda K et al.: Internal duplication and homology with bacterial transport proteins in the *mdr1* (P-glycoprotein) gene from multidrug resistance cells. *Cell*. 1986, 47, S.381-389,
- Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, Roninson IB: Internal duplication and homology with bacterial transport proteins in *mdr1* (P-glycoprotein) gene from multidrug-resistant human cells. *Cell*. 1986,
- Chin JE, Soffir R, Noonan KE, Choi K, Roninson IB: Structure and expression of the human MDR (P-glycoprotein) gene family. *Mol Cell Biol*. 1989, 9 (9), S.3808-3820,
- Chin KV, Ueda K, Pastan I, Gottesman MM: Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. *Science*. 1992, 255 (5043), S.459-462,
- Cholerton S, Daly AK, Idle JR: The role of individual human cytochromes P450 in drug metabolism and clinical response. *Trends Pharmacol Sci*. 1992, 13 (12), S.434-439,
- Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, Kim RB: Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. *Drug Metab Dispos*. 2000, 28 (6), S.655-660,
- Code EL, Crespi CL, Penman BW, Gonzalez FJ, Chang TK, Waxman DJ: Human cytochromes P4502B6 - Interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. *Drug Metab Dispos*. 1997, 25 (8), S.985-993,
- Collett A, Higgs NB, Sims E, Rowland M, Warhurst G: Modulation of the permeability of H₂ receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2. *J Pharmacol Exp Ther*. 1999, 288 (1), S.171-178,
- Cordon-Cardo C, O'Brien JP, Calsals D, Rittman-Grauer L, Biedler JL, Melamed MR, Bertino JR: Multi-drug resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. *Proc Natl Acad Sci USA*. 1989, 86, S.695-698,
- Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB: OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. *Drug Metab Dispos*. 1999, 27 (8), S.866-871,
- de Lange EC, Marchand S, van den Berg D, van der Sandt IC, de Boer AG, Delon A, Bouquet S, Couet W: In vitro and in vivo investigations of fluoroquinolones, effects of the P-glycoprotein efflux transporter on brain distribution of sparfloxacin. *Eur J Pharm Sci*. 2000, 12 (2), S.85-93,

- de Morais SMF, Schweikl H, Blaisdell J, Goldstein JA: Gene structure and upstream regulatory regions of human CYP2C9 and CYP2C18. *Biochem Biophys Res Commun.* 1993, *194*, S.194-201,
- Decleves X, Chevillard S, Charpentier C, Vielh P, Laplanche JL: A new polymorphism (N21D) in the exon 2 of the human MDR1 gene encoding the P-glycoprotein. *Hum Mutat.* 2000, *15* (5), S.486,
- Del Poeta G, Stasi R, Aronica G, Venditti A, Cox MC, Bruno A, Buccisano F, Masi M, Tribalto M, Amadori S, Papa G: Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. *Blood.* 1996, *87* (5), S.1997-2004,
- Dhooge C, De Moerloose B, Laureys G, Kint J, Ferster A, De Bacquer D, Philippe J, Benoit Y: P-glycoprotein is an independent prognostic factor predicting relapse in childhood acute lymphoblastic leukemia - results of a 6-year prespective study. *Br J Haematol.* 1999, *105*, S.676-683,
- Eckert C, Biondi A, Seeger K, Cazzaniga G, Hartmann R, Beyermann B, Pogodda M, Proba J, Henze G: Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukemia. *Lancet.* 2001, *358*, S.1239-1241,
- Efferth T, Sauerbrey A, Steinbach D, Gebhart E, Drexler HG, Miyachi H, Chitambar CR, Becker CM, Zintl F, Humeny A: Analysis of single nucleotide polymorphism C3435T of the multidrug resistance gene MDR1 in acute lymphoblastic leukemia. *Int J Oncol.* 2003, *23* (2), S.509-517,
- Evans WE, Relling MV, Rahman A, McLeod HL, Scott EP, Lin JS: Genetic basis for low prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans. *J Clin Invest.* 1993, *91* (5), S.2150-2154,
- Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, Decosterd LA, Furrer H, Opravil M, Pantaleo G, Retelska D, Ruiz L, Schinkel AH, Vernazza P, Eap CB, Telenti A, Swiss HIV Cohort Study: Response to antiretroviral treatment in HIV1 infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. *Lancet.* 2002, *359* (9300), S.30-36,
- Fojo AT, Shen DW, Mickley LA, Pastan I, Gottesmann MM: Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene. *J Clin Oncol.* 1987, *5* (12), S.1922-1927,
- Fromm MF: P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. *Int J Clin Pharmacol Ther.* 2000, *38* (2), S.69-74,

- Furuya H, Meyer UA, Gelboin HV, Gonzalez FJ: Polymerase chain reaction-directed identification, cloning and quantification of human CYP2C18 RNA. *Mol Pharmacol.* 1991, *40*, S.375-382,
- Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, Brockmoller J, Frotschl R, Kopke K, Gerloff T, Chernov JN, Roots I: Polymorphism of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. *Eur J Clin Pharmacol.* 2003, *59* (4), S.303-312,
- Gaynon PS, Qu RP, Chappell RJ, Willoughby ML, Tubergen DG, Steinherz PG, Trigg ME: Survival after relapse in childhood acute lymphoblastic leukemia: impact of site and time to first relapse - the Children's Cancer Group experience. *Cancer.* 1998, *82*:7, S.1387-1395,
- Geick A, Eichelbaum M, Burk O: Nuclear receptor response elements mediate induction of the intestinal MDR1 by rifampin. *J Biol Chem.* 2001, *276* (18), S.14581-14587,
- Goasguen JE, Dossot JM, Fardel O, Le Mee F, Le Gall E, Leblay R, Le Prise PY, Chaperon J, Fauchet R: Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. *Blood.* 1993, *81* (9), S.2394-2398,
- Goldie JH, Coldman AJ: Quantitative model for multiple levels of drug resistance in clinical tumors. *Cancer Treatment Reports.* 1983, *67*, S.923-930,
- Goldstein JA, de Morais SM: Biochemistry and molecular biology of the human CYP2C subfamily. *Pharmacogenetics.* 1994, *4*, S.285-299,
- Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, Lasker JM, Ghanayem BI: Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans. *Biochemistry.* 1994, *33*, S.1743-1752,
- Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, Pirker R, Green A, Crist W, Brodeur GM et al: Expression of a multidrug resistance gene in human cancer. *J Natl Cancer Instit.* 1989, *81* (2), S.116-124,
- Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD, Lander ES: Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. *Science.* 1999, *Vol. 286*; *5439*, S.531-537,
- Gotoh O: Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. *J Biol Chem.* 1992, *267* (1), S.83-90,

- Gottesmann MM, Pastan I: The multidrug transporter, a double-edged sword. *J Biol Chem.* 1988, 263 (25), S.12163-12166,
- Gottesmann MM, Pastan I: Resistance to multiple chemotherapeutic agents in human cancer cells. *Trends Pharmacol Sci.* 1988, 9 (2), S.54-58,
- Gray IC, Nobile C, Muresu R, Ford S, Spurr NK: A 2.4-megabase physical map spinning the CYP2C gene cluster on chromosome 10q24. *Genomics* . 1995, 28 (2), S.328-332,
- Greaves MF, Alexander FE: An infectious etiology for common acute lymphoblastic leukemia in childhood?. *Leukemia.* 1993, 7, S.349-360,
- Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, Kroemer HK: The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. *J Clin Invest.* 1999, 104 (2), S.147-153,
- Gruber A, Vitols S, Norgren S, Arestrom I, Peterson C, Bjorkholm M, Reizenstein P, Luthman H: Quantitative determination of MDR1 gene expression in leukaemic cells from patients with acute leukaemia. *Br J Cancer.* 1992, 66 (2), S.266-272,
- Guengerich FP, Kim DH: In vitro inhibition of dihydropyridine oxidation and aflatoxin B1 activation in human liver microsomes by naringenin and other flavonoids. *Carcinogenesis.* 1990, 11 (12), S.2275-2279,
- Guengerich FP, Shimada T: Oxidation of toxic and carcinogenic chemicals by human cytochrome P450 enzymes. *Chem Res Toxicol.* 1991, 4 (4), S.391-407,
- Hamada H, Tsuruo T: Functional role for the 170 to 180-kDa glycoprotein specific to drug-resistant tumour cells as revealed by monoclonal antibodies. *Proc Natl Acad Sci USA.* 1986, 3 (20), S.7785-7789,
- Hamada S, Kamada M, Furumoto H, Hirao T, Aono T: Expression of glutathione S-transferase-pi in human ovarian cancer as an indicator of resistance to chemotherapy. *Gynecol Oncol.* 1994, 52, S.313-319,
- Hamdy SI, Hiratsuka M, Narahara K, Endo N, El-Enany M, Moursi N, Ahmed MS, Mizugaki M: Genotype and allele frequencies of TPMT, NAT2, GST, SULT1A1 and MDR1 in an Egyptian population. *Br J Clin Pharmacol.* 2003, 55 (6), S.560-569,
- Harbott J, Ritterbach J, Ludwig WD, Bartram CR, Reiter A, Lampert F: Clinical significance of cytogenetic studies in childhood acute lymphoblastic leukemia: experience of the BFM trials. *Recent Results Cancer Res.* 1993, 131,

- Harrison DJ: Molecular mechanisms of drug resistance in tumours. *Journal of Pathology*. 1995, *175*, S.7-12,
- Harvey EB, Boice JD, Honeyman M et al.: Prenatal X-ray exposure and childhood cancer in twins. *N Engl J Med* . 1985, *312*, S.1079,
- Hayaishi O: Biological oxidations. *Annu Rev Biochem*. 1962, *31*, S.24-46,
- Hayashi SI, Watanabe J, Nakachi K, Kawajiri K: PCR detection of an A/G polymorphism within exon 7 of the CYP1A1 gene. *Nucleic Acids Res*. 1991, *19 (17)*, S.4797,
- Henze G: Childhood acute lymphoblastic leukemia. *Eur J Cancer*. Jan. 1997, *33 (1)*, S.8-9,
- Henze G, Fengler R, Hartmann R, Kornhuber B, Janka Schaub G, Niethammer D, Riehm H: Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL REZ BFM 85) A relapse study of the BFM group. *Blood*. 1991, *78*, S.1166-1172,
- Hitzl M, Drescher S, van der Kuip H, Schaeffeler E, Fischer J, Schwab M, Eichelbaum M, Fromm MF: The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. *Pharmacogenetics*. 2001, *11(4)*, S.293-298,
- Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, John A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U: Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. *Proc Natl Acad Sci USA*. 2000, *97 (7)*,
- Hoki Y, Fujimori A, Pommier Y: Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines. *Cancer Chemother Pharmacol*. 1997, *40*, S.433-438,
- Homolya L, Hollo Z, Germann UA, Pastan I, Gottesman M, Sarkadi B: Fluorescent cellular indicators are extruded by the multidrug resistance protein. *J Biol Chem*. 1993, *268*, S.21493-21496,
- Hu Y, Oscarson M, Johansson I, Yue QY, Dahl ML, Tabone M, Arinco S, Albano E, Ingelman-Sundberg M: Genetic polymorphism of human CYP2E1: characterization of two variant alleles. *Mol Pharmacol*. 1997, *51 (3)*, S.370-376,
- Ibeanu GG, Goldstein JA: Transcriptional regulation of human CYP2C genes. functional comparison of CYP2C9 and CYP2C18 promoter regions. *Biochemistry* . 1995, *34 (25)*, S.8028-8036,

- Illmer T, Schuler U, Thiede C, Schwarz U, Kim R, Gotthard S, Freund D, Schäkel U, Ehninger G, Schaich M: MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. *Cancer Res.* 2002, *62 (17)*, S.4955-4962,
- Inoue K, Yamazaki H, Shimada T: Linkage between the distribution of mutations in the CYP2C18 and CYP2C19 genes in the Japanese and Caucasian. *Xenobiotica.* 1998, *28 (4)*, S.403-411,
- Ito T, Yano I, Tanaka K, Inui KI: Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line LLC-PK1. *J Pharmacol Exp Ther.* 1997, *282 (2)*, S.955-960,
- Ivy SP, Olshefski RS, Taylor BJ, Patel KM, Reaman GH: Correlation of P-glycoprotein expression and function in childhood acute leukemia: a children's cancer group study. *Blood.* 1996, *88 (1)*, S.309-318,
- Jamroziak K, Mlynarski W, Balcerczak E, Mistygacz M, Trelinska J, Mirowski M, Bodalski J, Robak T: Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. *Eur J Haematol.* 2004, *72 (5)*, S.314-321,
- Jette L, Murphy GF, Leclerc JM, Beliveau R: Interaction of drugs with P-glycoprotein in brain capillaries. *Biochem Pharmacol.* 1995, *50*, S.1701-1709,
- Jurima-Romet M, Goldstein JA, Lebel M, Aubin RA, Foster BC, Walop W, Rode A: CYP2C19 genotyping and associated mephenytoin hydroxylation polymorphism in a Canadian Inuit population. *Pharmacogenetics.* 1998, *6 (4)*, S.329-339,
- Kakumoto m, Sakaeda T, Takara K, Nakamura T, Kita T, Yagami T, Kobayashi H, Okamura N, Okamura K: Effects of carvedilol on MDR1-mediated multidrug resistance: a comparison with verapamil. *Cancer Sci.* 2003, *94 (1)*, S.81-86,
- Kaminsky LS, de Morais SMF, Faletto MB, Dunbar DA, Goldstein JA: Correlation of human cytochrome P450 2C substrate specificities with primary structure: warfarin as a probe. *Molecul Pharmacol.* 1993, *43*, S.234-239,
- Kartner N, Riordan JR, Ling V: Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. *Science.* 1983, *221*, S.1285-1288,
- Kasahara K, Fujiwara Y, Nishio K, Ohmori T, Sugimoto Y, Komiya K: Metallothionein content correlates with the sensitivity of human small cell lung cancer lines to cisplatin. *Cancer Research.* 1991, *51*, S.3237-3242,

- Kato GJ, Quddus FF, Shuster JJ, Boyett J, Pullen JD, Borowitz MJ, Whitehead VM, Crist WM, Leventhal BG: High glucocorticoid receptor content of leukemic blasts is a favorable prognostic factor in childhood acute lymphoblastic leukemia. *Blood*. 1993, 82, S.2304-2309,
- Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S: The CYP1A1 gene and cancer susceptibility. *Crit Rev Oncol Hematol*. 1993, 14 (1), S.77-87,
- Kawajiri K, Nakachi K, Imai K, Yoshii A, Shinoda N, Watanabe J: Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene. *FEBS Lett*. 1990, 263 (1), S.131-133,
- Kelly JD, Eaton DL, Guengerich FP, Coulombe RA Jr. : Aflatoxin B1 activation in human lung. *Toxicol Appl Pharmacol*. 1997, 144 (1), S.88-95,
- Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, Wilkinson GR: The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV1 protease inhibitors. *J Clin Invest*. 1998, 101 (2), S.289-294,
- Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, Mc Kinsey J, Zhou S, Lan LB, Schuetz JD, Schuetz EG, Wilkinson GR: Identification of functionally variant MDR1 alleles among European Americans and African Americans. *Clin Pharmacol Ther*. 2001, 70 (2), S.189-199,
- Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR: Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. *Pharm Res* . 1999, 16 (3), S.408-414,
- Kishi S, Yang W, Boureau B, Morand S, Das S, Chen P, Cook EH, Rosner GL, Schuetz EG, Pui CH, Relling MV: Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. *Blood*. 2004, 103 (1), S.67-72,
- Klimecki WT, Futscher BW, Grogan TM, Dalton WS: P-glycoprotein expression and function in circulating blood cells from normal volunteers. *Blood*. 1994, 83, S.2451-2458,
- Klingenberg M: Pigments of rat liver microsomes. *Arch Biochem Biophys*. 1958, 75 (2), S.376-386,
- Klose TS, Blaisdell JA, Goldstein JA: Gene structure of CYP2C8 and extrahepatic distribution of human CYP2Cs. *J Biochem Mol Toxicol*. 1999, 13 (6), S.289-295,
- Klumper E, Pieters R, Veerman AJ, Huisman DR, Loonen AH, Hahlen K, Kaspers GJ, van Wering ER, Hartmann R, Henze G: In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. *Blood*. 1995, 86, S.3861-3868,

- Knutsen I, Mickley LA, Ried T, Green ED, du Manoir S, Schrock E, Macville M, Ning Y, Robey R, Polymeropoulos M, Torres R, Fojo T: Cytogenetic and molecular characterization of random chromosomal rearrangements activating the drug resistance gene, MDR1/P-glycoprotein, in drug -selected cell lines and patients with drug refractory ALL. *Genes Chromosomes Cancer*. 1998, *23 (1)*, S.44-54,
- Komai K, Sumida K, Kaneko H, Nakatsuka I: Identification of a new non-functional CYP2C18 allele in Japanese: substitution of T204 to A in exon 2 generates a premature stop codon. *Pharmacogenetics*. 1996, *6 (1)*, S.117-119,
- Kubota T, Hibi N, Chiba K: Linkage of mutant alleles of CYP2C18 and CYP2C19 in a Japanese population. *Biochem Pharmacol*. 1998, *55 (12)*, S.2039-2042,
- Kupfer A, Preisig R: Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. *Eur J Clin Pharmacol*. 1984, *26 (6)*, S.753-759,
- Lankas GR, Wise LD, Cartwright ME, Pippert T, Umbenhauer DR: Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. *Reprod Toxicol*. 1998, *12*, S.457-463,
- Leith CP, Kopecky KJ, Godwin J, Mc Counell T, Slovak ML, Chen IM, Head DR, Appelbaum FR, Willman CL: Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. *Blood*. 1997, *89 (9)*, S.3323-3329,
- Lemontt JF, Azzaria M, Gros P: Increased mdr gene expression and decreased drug accumulation in multidrug resistant human melanoma cells. *Cancer Research*. 1988, *48*, S.6348-6353,
- Liu J, Liu Y, Powell DA, Waalkes MP, Klaassen CD: Multidrug-resistance mdr1a/1b double knockout mice are more sensitive than wild type mice to acute arsenic toxicity, with higher arsenic accumulation in tissues. *Toxicology*. 2002, *170 (1-2)*, S.55-62,
- MacFarland A, Abramovich DR, Ewen SW, Pearson CK: Stage-specific distribution of P-glycoprotein in first-trimester and full-term human placenta. *Histochem J*. 1994, *26*, S.417-423,
- Mamiya K, Ieiri I, Miyahara S, Imai J, Furuumi H, Fukumaki Y, Ninomiya H, Tashiro N, Yamada H, Higushi S: Association of polymorphisms in the cytochrome P450 (CYP) 2C19 and 2C18 genes in Japanese epileptic patients. *Pharmacogenetics*. 1998, *8 (1)*, S.87-90,
- Mancy A, Antignac M, Minoletti C, Dijols S, Mouries V, Duong NT, Battioni P, Dansette PM, Mansuy D: Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites:

- particular efficiency and regioselectivity of P450 2Cs. *Biochemistry*. 1999, 38, S.14264-14270,
- Marie JP: P-glycoprotein in adult hematologic malignancies. *Hematol Oncol Clin North Am*. 1995, 9 (2), S.239-249,
- Marill J, Cresteil T, Lanotte M, Chabot GG: Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. *Mol Pharmacol* . 2000, 58, S.1341-1348,
- Mason HS: Mechanisms of oxygen metabolism. *Science*. 1957, 125 (3259), S.1185-1188,
- Matsuzaki J, Yamamoto C, Miyama T, Takanaga H, Matsuo H, Ishizuka H, Kawahara Y, Kuwano M, Naito M, Tsuruo T, Sawada Y: Contribution of the P-glycoprotein to bunitrolol efflux across blood-brain barrier. *Biopharm Drug Dispos*. 1999, 20 (2), S.85-90,
- McMahon B: Prenatal X-ray exposure and twins. *N Engl J Med*. 1985, 312, S.541,
- McNeil DE, Coté TR, Clegg L et al.: SEER update of incidence and trends in pediatric malignancies: acute lymphoblastic leukemia. *Med. Pediatr. Oncol.* 2002, 39(6),
- Meyer UA: The molecular basis of genetic polymorphisms of drug metabolism. *J Pharm*. 1994, 46, S.409-415,
- Mickley LA, Lee JS, Weng Z, Zhan Z, Alvarez M, Wilson W, Bates SE, Fojo T: Genetic polymorphism in MDR1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors. *Blood*. 1998, 91 (5), S.1749-1756,
- Mike V, Meadows AT, D'Angio GJ: Incidence of second malignant neoplasms in children: results of an international study. *Lancet*. Band 2. 1982, S.1326,
- Miller RW: Relation between cancer and congenital defects: an epidemiologic evaluation. *J. Natl. Cancer Inst.* 1968, 40, S.554-557, discussion 552-553,
- Mizugaki M, Hiratsuka M, Agatsuma Y, Matsubara Y, Fujii K, Kure S, Narisawa K: Rapid detection of CYP2C18 genotypes by real-time fluorescence polymerase-chain reaction. *J Pharm Pharmacol*. 2000, 52 (2), S.199-205,
- Moriya Y, Nakamura T, Harinouchi M, Sakaeda T, Tamura T, Aoyama N, Shirakawa T, Gotoh A, Fujimoto S, Matsuo M, Kasuga M, Okumura K: Effects of polymorphisms of MDR1, MRP1 and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects. *Biol Pharm Bull*. 2002, 25 (10), S.1356-1359,
- Nakamura T, Sakaeda T, Harinouchi M, Tamura T, Aoyama N, Shirakawa T, Matsuo M, Kasuga M, Okumura K: Effects of the mutation (C3435T) at exon 26 of the MDR1 gene on expression

- level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. *Clin Pharmacol Ther.* 2002, *71* (4), S.297-303,
- Nebert DW, Adesnik M, Coon MJ, Estabrook RW, Gonzalez FJ, Guengerich FP, Gunsalus JC, Johnson EF, Kemper B, Levin W et al. : The P450 gene subfamily: recommended nomenclature. *DNA.* 1987, *6* (1), S.1-11,
- Nedelcheva V, Gut I: P450 in the rat and man: methods of investigation, substrate specificities and relevance to cancer. *Xenobiotica.* 1994, *24* (12), S.1151-1175,
- Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC, Nebert DW: P450 - update on new sequences, gene mapping, accession numbers and nomenclature. *Pharmacogenetics.* 1996, *6*, S.1-42,
- Nishimura M, Yaguti H, Yoshitsugu H, Naito S, Satoh T: Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. *Yakugaku Zasshi.* 2003, *123* (5), S.369-375,
- Niwa T, Fujimoto M, Kishimoto K, Yabusaki Y, Ishibashi F, Katagiri M: Metabolism and interaction of bisphol A in human hepatic cytochrome P450 and steroidogenic CYP17. *Biol Pharm Bull.* 2001, *24*, S.1064-1067,
- Niwa T, Sato R, Yabusaki Y, Ishibashi F, Katagiri M: Contribution of human hepatic cytochrome P450 and steroidogenic CYP17 to the N-demethylation of aminopyrine. *Xenobiotica.* 1999, *29*, S.187-193,
- Nogae I, Kohno K, Kikuchi J, Kuwano M, Akiyama s, Kiue A, Suzuki K, Yoshida Y, Cornwell MM, Pastan I et al: Analysis of structural features of dihydropyridine analogs needed to reverse multidrug resistance and to inhibit photoaffinity labeling of P-glycoprotein. *Biochem Pharmacol.* 1989, *38* (3), S.519-527,
- Pauli-Magnus C, Mürdter T, Godel A, mettang T, Eichelbaum M, Klotz U, Fromm MF: P-glycoprotein-mediated transport of digitoxin, alpha-methyl digoxin and beta-acetyldigoxin. *Naunyn Schmiedebergs Arch Phamacol.* 2001, *363*, S.337-343,
- Pauli-Magnus C, von Richter O, Burk O, Ziegler A, Mettang T, Eichelbaum M, Fromm MF: Characterization of the major metabolites of verapamil as substrate and inhibitor of P-glycoprotein. *J Pharmacol Exp Ther.* 2000, *293* (2), S.376-382,
- Pinedo HM, Giaccone G: P-glycoprotein: a marker of cell-cell behavior. *New Engl J Med.* 1995, *333* (21), S.1417-1419,
- Rabitts TH: Chromosomal translocations in human cancer. *Nature.* 1994, *Vol. 372*, *6502*, S.143-149,

- Rao US, Fine RL, Scarborough GA: Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. *Biochem Pharmacol.* 1994, *48* (2), S.287-292,
- Raviv Y, Pollard HB, Bruggeman EP, Pastan I, Gottesman MM: Photosensitized labeling of the functional multidrug transporter in living drug-resistant tumor cells. *J Biol Chem.* 1990, *265*, S.3975-3980,
- Relling MV: Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs?. *Ther Drug Monit.* 1996, *18*, S.350-356,
- Richardson TH, Griffin KJ, Jung F, Raucy JL, Johnson EF: Targeted antipeptide antibodies to cytochrome P450 2C18 based on epitope mapping of an inhibitory monoclonal antibody to P450 2C51. *Arch Biochem Biophys.* 1997, *338* (2), S.157-164,
- Rivera GK, Hudson MM, Liu Q, Benaim E, Ribeiro RC, Crist WM, Pui CH: Effectiveness of intensified rotational combination chemotherapy for late hematologic relapse of childhood acute lymphoblastic leukemia. *Blood.* 1996, *88*, S.831-837,
- Romkes M, Faletto MB, Blaisdell JA, Raucy JL, Goldstein JA: Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450 2C subfamily. *Biochemistry.* 1991, *30*, S.3247-3255,
- Romkes M, Faletto MB, Raucy JL, Blaisdell J, Lasker JM, Goldstein JA: Cloning and expression of complementary DNAs for multiple members of the human P450IIC subfamily. *Biochemistry.* 1993, *32* (5), S.1350,
- Roninson IB, Chin JE, Choi KG, Gros P, Housman DE, Fojo A, Shen DW, Gottesman MM, Pastan I: Isolation of human *mdr* DNA sequences amplified in multidrug-resistant KB carcinoma cells. *Proc Natl Acad Sci USA.* 1986, *83* (12), S.4538-4542,
- Roy P, Yu LJ, Crespi CL, Waxman DJ: Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. *Drug Metab Dispos.* 1999, *27* (6), S.655-666,
- Rubnitz JE, Look AT: Molecular genetics of childhood leukemias. *J Pediatr Haematol Oncol.* 1998, *Vol. 20, Nr. 1*, S.1-11,
- Sadowitz PD, Smith SD, Shuster J, Wharam MD, Buchanan GR, Rivera GK: Treatment of late bone marrow relapse in children with acute lymphoblastic leukemia: A Pediatric Oncology Group study. *Blood.* 1993, *81*, S.602-609,
- Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T: Human P-glycoprotein transports cyclosporin A and FK 506. *J Biol Chem.* 1993, *268*, S.6077-6080,

- Sanfilippo O, Ronchi E, De Marco C, Di Fronzo G, Silvestrini R: Expression of P-glycoprotein in breast cancer tissue and in vitro resistance to doxorubicin and vincristine. *Eur J Cancer*. 1991, 27 (2), S.155-158,
- Sarkadi B, Price EM, Boucher RC, Germann UA, Scarborough GA: Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. *J Biol Chem*. 1992, 267 (7), S.4854-4858,
- Sawyers CL: Molecular genetics of acute leukemia. *Lancet*. 1997, Vol. 349; 9042, S.196-200,
- Schaeffeler E, Eichelbaum M, Brinkmann U, Penger A, Asante-Poku S, Zanger UM, Schwab M: Frequency of C3435T polymorphisms of MDR1 gene in African people. *Lancet*. 2001, 358 (9279), S.383-384,
- Schalasta G, Roth B, Enders G: Rapid typing of the codon 129 polymorphism of the human prion protein gene by combined real-time PCR and melting curve analysis. *Clin Lab*. 2002, 48 (1-2), S.25-30,
- Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, Van der Valk MA, Robanus-Maandag EC, te Riele HP, Berns AJM, Borst P: Disruption of the mouse *mdr1a* P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. *Cell*. 1994, 77, S.491-502,
- Schinkel AH, Wagenaar E, Mol CA, van Deemter L: P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. *J Clin Invest*. 1996, 97, S.2517-2524,
- Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P: Absence of the *mdr1a* P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin and cyclosporine A. *J Clin Invest*. 1995, 96, S.1698-1705,
- Schoenlein PV, Shen DW, Barrett JT, Pastan I, Gottesman MM: Double minute chromosomes carrying the human multidrug resistance 1 and 2 genes are generated from the dimerization of submicroscopic circular DNAs in colchicine-selected KB carcinoma cells. *Mol Biol Cell*. 1992, 3 (5), S.507-520,
- Schrapppe M, Camitta P, Pui CH et al.: Long-term results of large prospective trials in childhood acute lymphoblastic leukemia. *Leukemia*. 2000, 14, S.2193-2194,
- Schuetz EG, Schinkel AH, Relling MV, Schuetz JD: P-glycoprotein: a major determinant of rifampicin inducible expression of cytochrome P450 3A in mice and humans. *Proc Natl Acad Sci USA*. 1996, 93 (9), S.4001-4005,

- Schuetz EG, Yasuda K, Arimori K, Schuetz JD: Human MDR1 and mouse *mdr1a* P-glycoprotein alter the cellular retention and disposition of erythromycin, but not of retinoic acid or benzo(a)pyrene. *Arch Biochem Biophys* . 1998, *350* (2), S.340-347,
- Seeger K, Adams HP, Buchwald D, Beyermann B, Kremens B, Niemeyer C, Ritter J, Schwabe D, Harms D, Schrappe M, Henze G: TEL-AML1 fusion transcript in relapsed childhood acute lymphoblastic leukemia. The Berlin-Frankfurt-Munster Study Group. *Blood*. 1998, *91*(5), S.1716-1722,
- Seeger K, Stackelberg A, Taube T, Buchwald D, Korner G, Suttorp M, Dorffel W, Tausch W, Henze G: Relapse of TEL-AML1-positive acute lymphoblastic leukemia in childhood: a matched-pair analysis. *J Clin Oncol*. 2001, *19* (13), S.3188-3193,
- Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP: Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. *J Pharmacol Exp Ther*. 1994, *270* (1), S.414-423,
- Siegmund W, Ludwig K, Giessmann T, Dazert P, Schroeder E, Sperker B, Warzok R, Kroemer HK, Cascorbi I: The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. *Clin Pharmacol Ther*. 2002, *72* (5), S.572-583,
- Smith MA, Ries LA, Gurney JG et al.: Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. National Cancer Institute, SEER Program, Leukemia. 1999, *NIH Pub. No. 99-4649*,
- Soldner A, Benet LZ, Mutschler E, Christians U: Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and Caco-2 cell monolayers. *Br J Pharmacol*. 2000, *129* (6), S.1235-1243,
- Sonneveld P: Multidrug resistance in hematological malignancies. *J Int Med*. 2000, *247*, S.521-534,
- Sonneveld P, Durie BG, Lokhorst HM, Marie JP, Solbu G, Suci S, Zittoun R, Lowenberg B, Nooter K : Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON. *Lancet*. 1992, *340* (8814), S.255-259,
- Spareboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer Dk, Borst P, Nooijen WJ, Beijnen JH, van Tellingen O: Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. *Proc Natl Acad Sci USA*. 1997, *94*, S.2031-2035,

- Stackelberg A, Hartmann R, Ritter J, Nuereberger W, Klingebiel T, Kretschmann A, Henze G: Male gender as an independent adverse risk factor for children with isolated CNS relapse of ALL. Israeli-German binational conference: current concepts in pediatric hematology-oncology. 1999, *Abstract Vol 21*,
- Stanulla M, Schaeffeler E, Schrappe M, Arens S, Rathmann A, Welte K, Eichelbaum M, Zanger UM, Schwab M: An association between MDR1 C3435T polymorphism and CNS relapse in childhood ALL. *Eur J Clin Pharmacol*. 2001, *57*, S.A28,
- Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR: Genetic analysis of the human cytochrome P450 CYP2C9 locus. *Pharmacogenetics*. 1996, *6 (5)*, S.429-439,
- Sugiyama Y, Kato Y, Chu X: Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolites SN-38, and its glucuronide: role of canalicular multispecific organic anion transport and P-glycoprotein. *Cancer Chemother Pharmacol*. 1998, *42 (Suppl.)*, S.S44-S49,
- Szabo D, Keyzer H, Kaiser HE, Molnar J: Reversal of multidrug resistance of tumor cells . *Anticancer Res*. 2000, *20 (6B)*, S.4261-4274,
- Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, Takahashi M, Kurata Y, Kigawa J, Higuchi S, Terakawa N, Otsubo K: Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. *J Pharmacol Exp Ther* . 2001, *279(3)*, S.1137-1143,
- Thiebaut F, Tsuruo H, Hamada H, Gottesmann MM, Pastan I, Willingham MC: Cellular localization of the multiple drug-resistance gene product P-glycoprotein in normal human tissues. *Proc Natl Acad Sci USA*. 1987, *84*, S.7735-7738,
- Thummel KE, Kunze KL, Shen DD: Enzyme-catalysed processes of first-pass hepatic and intestinal drug extraction. *Advanced Drug Deliv Rev*. 1997, *27*, S.99-127,
- Tsuneoka Y, Matsuo Y, Okuyama E, Watanabe Y, Ichikawa Y: Genetic analysis of the cytochrome P-450IIC18 (CYP2C18) gene and a novel member of the CYP2C subfamily. *FEBS Lett* . 1996, *384 (3)*, S.281-284,
- van den Heuvel-Eibrink MM, Wiemer EA, de Boevere MJ, van der Holt B, Vossebeld PJM, Pieters R, Sonneveld P: MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia. *Blood*. 2001, *97 (11)*, S.3605-3611,
- van Dongen JJM, Seriu T, Panzer-Grümayer ER et al.: Prognostic value of minimal residual disease in childhood acute lymphoblastic leukemia: A prospective study of the International BFM Study Group. *Lancet*. 1998, *352*, S.1731-1738,

- van Kalken CK, Broxterman HJ, Pinedo HM, Feller N, Dekker H, Lankelma J, Giaccone G: Cortisol is transported by the multidrug resistance gene product P-glycoprotein. *Br J Cancer*. 1993, *67* (29), S.284-289,
- van Kalken CK, Pinedo HM, Giaccone G: Multidrug resistance from the clinical point of view. *Eur J Cancer*. 1991, *27* (11), S.1481-1486,
- Verstuyft C, Schwab M, Schaeffeler E, Kerb R, Brinkmann U, Jaillon P, Funck-Bretano C, Becquemont L: Digoxin pharmacokinetics and MDR1 genetic polymorphisms. *Eur J Clin Pharmacol*. 2003, *58* (12), S.809-812,
- Wacher VJ, Wu CY, Benet LZ: Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. *Mol Carcinog*. 1995, *13* (3), S.129-134,
- Walker D, Flinois JP, Monkman SC, Beloc C, Boddy AV, Cholerton S, Daly AK, Lind MJ, Pearson ADJ, Beaune PH, Idle JR: Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. *Biochem Pharmacol*. 1994, *47* (7), S.1157-1163,
- Warnecke P, Seeber S: Sites of action of Vinca alkaloids in protein and nucleic acid metabolism of leukemic lymphocytes in vitro. *Zeitschr Krebsforschung*. 1968, *71*(4), S.361-367,
- Wheeler K, Chessells JM, Bailey CC, Richards S: Treatment-related deaths during induction and first remission in childhood ALL. *Med Pediatr Oncol*. 1994, *23* (4), S.A26,
- Wilkinson GR, Guengerich FP, Branch RA: Genetic polymorphism of S-mephenytoin hydroxylation. *Pharmacol Ther*. 1989, *43* (1), S.53-76,
- Wils P, Phung-Ba V, Warnery A, Lechardeur D, Raeissi S, Hidalgo IJ, Scherman D: Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. *Biochem Pharmacol*. 1994, *48* , S.1528-1530,
- Winick NJ, McKenna RW, Shuster JJ, Schneider NR, Borowitz MJ, Bowman WP, Jacaruso D, Kamen BA, Buchanon GR: Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with Etoposide. *J Clin Oncol*. 1993, *11*,
- Wuchter C, Leonid K, Ruppert V, Schrappe M, Buchner T, Schoch C, Haferlach T, Harbott J, Ratei R, Dorken B, Ludwig WD: Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. *Haematologica*. 2000, *85* (7), S.711-721,

- Yang JM, Vassil AD, Hait WN: Activation of phospholipase C induces the expression of the multidrug resistance (MDR1) gene through the Raf-MAPK pathway. *Mol Pharmacol.* 2001, *60* (4), S.674-680,
- Yengi LG, Xiang Q, Pan J, Scatina J, Kao J, Ball SE, Fruncillo R, Ferron G, Roland Wolf C: Quantification of cytochrome P450 mRNA levels in human skin. *Anal Biochem.* 2003, *103-110*,
- Zamora JM, Pearce HL, Beck WT: Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. *Mol Pharmacol.* 1988, *33* (4), S.454-462,
- Zaphiropoulos PG: Exon skipping and circular RNA formation in transcripts of the human cytochrome P450 2C18 gene in epidermis and of the rat androgen binding protein gene in testis. *Mol Cell Biol.* 1997, *17* (6), S.2985-2993,
- Zhu-Ge J, Yu YN, Li X, Qian YL: Cloning of cytochrome P450 2C9 cDNA from human liver and its expression in CHL cells. *World of Gastroenterol.* 2002, *8*, S.318-322,
- Zhu-Ge J, Yu YN, Qian YL, Li X: Establishment of a transgenic cell line stably expressing human cytochrome P450 2C18 and identification of a CYP2C18 clone with exon 5 missing. *World J Gastroenterol.* 2002, *8* (5), S.888-892.